非小细胞肺癌患者恶性胸腔积液中EGFR基因突变
비소세포폐암환자악성흉강적액중EGFR기인돌변
EGFR mutation in malignant pleural effusion of non-small cell lung cancer
  • 万方数据
    国际肿瘤学杂志 국제종류학잡지
    JOURNAL OF INTERNATIONAL ONCOLOGY
    2013年 8期 595-597 ,共3页

    楚慧丽%梁秀菊%毕经旺

    초혜려%량수국%필경왕

    癌,非小细胞肺%受体,表皮生长因子%突变%恶性胸腔积液 癌,非小細胞肺%受體,錶皮生長因子%突變%噁性胸腔積液
    암,비소세포폐%수체,표피생장인자%돌변%악성흉강적액
    Carcinoma,non-small cell lung%Receptor,epidermal growth factor%Mutation%Malignant pleural effusion
    非小细胞肺癌患者接受表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)治疗前进行EGFR检测已经成为共识.恶性胸腔积液是非小细胞肺癌(NSCLC)患者常见的临床表现,采用不同方法对胸腔积液细胞及游离核酸提取后进行EGFR检测,对预测EGFR-TKI的疗效有着良好前景.
    비소세포폐암환자접수표피생장인자수체-락안산격매억제제(EGFR-TKI)치료전진행EGFR검측이경성위공식.악성흉강적액시비소세포폐암(NSCLC)환자상견적림상표현,채용불동방법대흉강적액세포급유리핵산제취후진행EGFR검측,대예측EGFR-TKI적료효유착량호전경.
    EGFR testing has become the consensus before epidermal growth factor-tyrosine kinase inhibitorrs (EGFR-TKIs) treatment in non-small cell lung cancer(NSCLC) patients.Malignant pleural effusion is the common clinical manifestation in NSCLC patients,and EGFR testing by using different methods in pleural effusion cells and free nucleic acids has good prospect for predicting the efficacy of EGFR-TKIs.
    원문보기 원문다운로드 사이트로이동
저자의 최근 논문